PT - JOURNAL ARTICLE AU - Vilar, Jose M. G. AU - Saiz, Leonor TI - The evolving worldwide dynamic state of the COVID-19 outbreak AID - 10.1101/2020.11.26.20239434 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.26.20239434 4099 - http://medrxiv.org/content/early/2020/11/30/2020.11.26.20239434.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.11.26.20239434.full AB - The dynamic characterization of the COVID-19 outbreak is critical to implement effective actions for its control and eradication but the information available at a global scale is not sufficiently reliable to be used directly. Here, we integrate multiple data sources through dynamical constraints to quantify its temporal evolution and controllability around the world and within the United States. Overall, the numbers of actively infectious individuals have remained high beyond targeted controllability, with worldwide estimates of 10.24 million on November 24, 2020, totaling in 266.1 million cumulative infections growing at a rate of 11.12 million new infections per week. The actively infectious population reached a local maximum of 7.33 million on July 16, 2020 and remained virtually stagnant at a global scale, with growth rates for most countries around zero that compensated each other, until reverting to net growth on September 22, 2020. We validated the approach, contrasting with prevalence data and the effects of nonpharmaceutical interventions, and we identified general patterns of recession, stabilization, and resurgence. The diversity of dynamic behaviors of the outbreak across countries is paralleled by those of states and territories in the United States, converging to remarkably similar global states in both cases. Our results offer precise insights into the dynamics of the outbreak and an efficient avenue for the estimation of the prevalence rates over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJ.M.G.V. acknowledges support from Ministerio de Ciencia e Innovacion under grant PGC2018-101282-B-I00 (MCI/AEI/FEDER, UE). L.S. acknowledges support from the University of California, Davis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails for accessing the data sources are provided in the manuscript. https://github.com/Covid19Dynamics/trajectories